Evidence map›Paper›PMID 40357282›Full record

ArticleFrontiers in medicine2025

Clinical features of

Aixiang Wu, Wei Gai, Yuxin Guo, Chenjie Zhou, Yan Xu, Xiaojing Zhang, Huajun Wang

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Prognosis of Patients Infected WithJournal of general and family medicine · 2026
    Article
  2. DisseminatedInfection and drug resistance · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aixiang WuDepartment of Pharmacy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Wei GaiWillingMed Technology (Beijing) Co., Ltd., Beijing, China.
Yuxin GuoWillingMed Technology (Beijing) Co., Ltd., Beijing, China.
Chenjie ZhouDepartment of Intensive Care Unit, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Yan XuDepartment of Pharmacy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Xiaojing ZhangWillingMed Technology (Beijing) Co., Ltd., Beijing, China.
Huajun WangDepartment of Intensive Care Unit, The Affiliated People's Hospital of Ningbo University, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Talaromycosis, caused by Methods: Patients diagnosed with Results: Seven patients were diagnosed with Conclusion: Early diagnosis and combination therapy are critical for

Indexed as

clinical characteristicsinfectionmetagenomic next-generation sequencingTalaromyces marneffeitreatment

Identifiers

PMID40357282
PMCPMC12066333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.